InvestorsHub Logo
Followers 3
Posts 190
Boards Moderated 0
Alias Born 05/16/2013

Re: None

Saturday, 06/13/2015 12:29:52 AM

Saturday, June 13, 2015 12:29:52 AM

Post# of 426564
I believe the Amarin strategy to use lawsuits to chip away at the FDA has been more successful than many of us assumed. We thought the NCE suit was negligible - turns out it's not. Many now believe the very narrow scope of the 1st Amendment suit is minor, but it's really a cleverly designed, poison-tipped spear. Regardless of the innocent seeming, narrowly focused complaint, the judge must establish his or her rationale for their ruling. Regardless of the narrow scope of Amaron's complaint, the judge's rationale could easily extend to all sorts of other "speech" issues for pharma. The FDA has seriously erred in asking the Justice department to defend their ridiculous actions, and I assume the deeper their attorneys get involved in this, the more urgently they will advise the FDA to find a more defensible solution. Really, it's been a brilliant strategy so far.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News